» Sign in / Register

HIV-1 p24 - 24kDa

Human Immunodeficiency Virus 1 Antigen

recombinant, E. coli

Cat. No. Amount Price (EUR) Buy / Note
PR-1266 10 μg 207,00 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped on blue ice

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 24 kDa

Purity: > 90 % (SDS-PAGE, HPLC)

Form: lyophilized (Reconstitute in water or PBS)

Human immunodeficiency virus type-1 (HIV-1) capsid protein p24 is the main component of tubular core in the mature virus particle. Decrease in the level of antibodies to p24 and p24 antigen has been considered to be one of the most useful prognostic markers. Determination of p24 antigen, as well as anti-p24 antibodies, has vast diagnostic value. Therefore, most diagnostic kits to detect HIV antibodies use p24 as an integral component in addition to envelope glycoproteins. Inhibition of capsid formation can be an effective therapeutic strategy.

Selected References:
Barletta et al. (2004) Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen. Am. J. Clin. Pathol. 122:20.
Barbouche et al. (1999) False-positive HIV-1 p24 antigenemia with unusual pattern of neutralization. Arch. Inst. Pasteur. Tunis. 76:11.
Bonard et al. (2003) Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Cote d'Ivoire, West Africa. J. Acquir. Immune. Defic. Syndr. 34:267.
Eyeson et al. (2003) Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIVexposed- seronegative subjects. AIDS. 17:2299.
Ribas et al. (2003) Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J. Virol. Methods. 113:29.
Schupbach et al. (2003) HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 33:292.